Sanofi bets on safer aspirin combos with $35M Pozen deal

Sanofi ($SNY) is handing over a $15 million upfront payment along with promises of $20 million in precommercialization milestones to partner with Chapel Hill, NC-based Pozen ($POZN) on a pair of new-and-improved aspirins that avoid some common side effects. Report

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.